| # | Title | Journal | Year | Citations |
|---|
| 1 | Activated Platelets Release Two Types of Membrane Vesicles: Microvesicles by Surface Shedding and Exosomes Derived From Exocytosis of Multivesicular Bodies and -Granules | Blood | 1999 | 1,292 |
| 2 | High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis | New England Journal of Medicine | 2000 | 609 |
| 3 | Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study | Lancet Haematology,the | 2020 | 244 |
| 4 | Multivesicular Bodies Are an Intermediate Stage in the Formation of Platelet α-Granules | Blood | 1998 | 213 |
| 5 | Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus | Arteriosclerosis, Thrombosis, and Vascular Biology | 2006 | 191 |
| 6 | Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits | Nature Medicine | 1999 | 123 |
| 7 | Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium | Blood | 1984 | 122 |
| 8 | IRS-1 Mediates Inhibition of Ca2+ Mobilization by Insulin via the Inhibitory G-protein Gi | Journal of Biological Chemistry | 2004 | 96 |
| 9 | Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granules | Blood | 1998 | 84 |
| 10 | High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysis | Cancer Treatment Reviews | 2007 | 80 |
| 11 | Aging, physical conditioning, and exercise-induced changes in hemostatic factors and reaction products | Journal of Applied Physiology | 2000 | 63 |
| 12 | Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting | Blood Advances | 2019 | 60 |
| 13 | Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes | Blood Advances | 2019 | 42 |
| 14 | Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study | Blood | 2019 | 42 |
| 15 | A Fifty Percent Reduction of Platelet Surface Glycoprotein Ib Does Not Affect Platelet Adhesion Under Flow Conditions | Blood | 1998 | 40 |
| 16 | Activated Platelets Release Two Types of Membrane Vesicles: Microvesicles by Surface Shedding and Exosomes Derived From Exocytosis of Multivesicular Bodies and -Granules | Blood | 1999 | 40 |
| 17 | First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) | Blood | 2020 | 28 |
| 18 | Glucose Uptake via Glucose Transporter 3 by Human Platelets Is Regulated by Protein Kinase B | Journal of Biological Chemistry | 2005 | 27 |
| 19 | Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial | Blood | 2018 | 26 |
| 20 | Plasma Fibrinogen Inhibits Platelet Adhesion in Flowing Blood to Immobilized Fibrinogen | Arteriosclerosis, Thrombosis, and Vascular Biology | 1996 | 25 |
| 21 | Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study | Journal of Clinical Oncology | 2022 | 22 |
| 22 | Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma | Blood Advances | 2021 | 22 |
| 23 | Immunoelectron microscopic localization of actin, alpha-actinin, actin-binding protein and myosin in resting and activated human blood platelets | European Journal of Cell Biology | 1989 | 18 |
| 24 | Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells | Cell Death and Disease | 2021 | 15 |
| 25 | Platelet adhesion | Seminars in Hematology | 1995 | 12 |
| 26 | Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID‐19 Pandemic | HemaSphere | 2020 | 11 |
| 27 | Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation | Bone Marrow Transplantation | 1992 | 11 |
| 28 | TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product | Molecular Therapy | 2020 | 10 |
| 29 | Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile | Bone Marrow Transplantation | 2020 | 9 |
| 30 | Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT | Bone Marrow Transplantation | 2022 | 8 |
| 31 | Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy | Journal of Neurology | 2022 | 8 |
| 32 | Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression | Leukemia and Lymphoma | 2022 | 8 |
| 33 | Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018 | British Journal of Haematology | 2022 | 7 |
| 34 | Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation | CPT: Pharmacometrics and Systems Pharmacology | 2020 | 6 |
| 35 | Impaired Cytoskeletal and Membrane Biophysical Properties of Acanthocytes in Hypobetalipoproteinemia – A Case Study | Frontiers in Physiology | 2021 | 6 |
| 36 | Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1 | Cancers | 2021 | 6 |
| 37 | Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma | HemaSphere | 2022 | 6 |
| 38 | The ‘monocytic’ cell line I937 displays typical B cell characteristics | Immunology Letters | 1996 | 5 |
| 39 | Endomyocardial biopsy with co-localization of a lymphoplasmacytic lymphoma and AL amyloidosis | Cardiovascular Pathology | 2021 | 5 |
| 40 | A fifty percent reduction of platelet surface glycoprotein Ib does not affect platelet adhesion under flow conditions | Blood | 1998 | 5 |
| 41 | Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis | Blood Cancer Journal | 2021 | 4 |
| 42 | Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma | Blood Advances | 2021 | 4 |
| 43 | Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001 | Blood | 2020 | 4 |
| 44 | Patient preferences regarding treatment options for Waldenström's macroglobulinemia: A discrete choice experiment | Cancer Medicine | 0 | 4 |
| 45 | Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients | Blood | 2021 | 3 |
| 46 | Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations | Blood | 2020 | 3 |
| 47 | Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition | Haematologica | 2022 | 3 |
| 48 | Carfilzomib Combined With Thalidomide and Low‐dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial | HemaSphere | 2020 | 2 |
| 49 | Conditional relative survival in Waldenström’s macroglobulinaemia: a population‐based study in The Netherlands | British Journal of Haematology | 2021 | 2 |
| 50 | Identification of Biomarkers That Are Associated with Clinical Complications of Hemoglobin SC Disease and Sickle Cell Anemia | Blood | 2021 | 2 |
